Key Highlights

  • 16 is the November 2026 date on which Kyntra Bio, Inc. (NASDAQ:KYNB) is scheduled to report third quarter results, with the FG-3246 interim analysis and a roxadustat Phase 3 start both targeted for the fourth quarter.
  • 95.7 million USD is the cash, equivalents, investments and receivables balance at June 30, 2026, which management expects to fund operations into 2028, against a market Capitalization near USD 14.5 million.
  • 11.97 million USD is the second quarter net income, or USD 2.96 per share, driven by a USD 30.9 million gain on deconsolidation of a subsidiary, while the loss from operations was USD 17.6 million.
  • 16.1 million USD is the total operating costs for the second quarter, up from USD 13.4 million, with Research and Development at USD 6.8 million and selling, general and administrative expense at USD 9.3 million.

What Investors Expect From Kyntra Bio, Inc. (NASDAQ:KYNB) on November 16, 2026

Kyntra Bio, Inc. is scheduled to report third quarter 2026 results on November 16, 2026. Published market data shows a share price of USD 3.59 at the November 12, 2026 close and a market capitalization of about USD 14.5 million. The comparison base is a second quarter in which reported Net Income of USD 11.97 million included a one-time USD 30.9 million deconsolidation gain, so operating results, not the headline, are the better guide. Management has pointed to two fourth quarter milestones, an interim analysis of FG-3246 and the start of a roxadustat Phase 3 trial.

The Rationale: Last Reported Quarter and Management Outlook for Kyntra Bio, Inc. (NASDAQ:KYNB)

In the quarter ended June 30, 2026, total Revenue was negative USD 1.5 million, reflecting drug product revenue of negative USD 1.577 million, against USD 1.3 million a year earlier. Loss from operations widened to USD 17.6 million from USD 12.1 million and interest expense was USD 2.4 million. The prior-year quarter showed a net loss of USD 7.6 million, or USD 1.88 per share. FG-3246, a CD46-targeting antibody drug conjugate, is in a Phase 2 monotherapy trial in metastatic castration-resistant prostate cancer that is still enrolling, and the Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes is finalized.

Valuation, Liquidity and Risks for Kyntra Bio, Inc. (NASDAQ:KYNB)

At June 30, 2026, cash was USD 50.6 million, short-term investments USD 40.7 million, Long-Term Investments USD 4.0 million and receivables USD 0.3 million, for USD 95.7 million in total. That liquidity is about 6.6 times the market capitalization of roughly USD 14.5 million, calculated. Total liabilities were USD 109.2 million, including a USD 70.5 million noncurrent Liability tied to the sale of future revenues, and the total Deficit was USD 29.6 million. Because the market capitalization is under USD 100 million, the stock is small-cap and can be volatile. Risks include trial outcomes, funding the roxadustat program and a partner path.

Where Things Stand

Where things stand: Kyntra Bio, Inc. (NASDAQ:KYNB) reports on November 16, 2026 with USD 95.7 million of liquidity, a runway into 2028 and weighted average shares of about 4.048 million. First-half research and development was USD 14.4 million and selling, general and administrative expense USD 15.1 million, producing a six-month net loss of USD 3.2 million, or USD 0.80 per share. Roxadustat Phase 3 initiation depends on a partner or internal funding path, and the FG-3246 interim analysis is expected in the fourth quarter of 2026. Operating cost trends and any update to milestone timing are the items to watch. This article is informational and is not Investment advice.